NEW YORK (GenomeWeb) – Curetis reported today a 38 percent drop in revenues for the full-year 2016, reflecting the receipt of nonrecurring Unyvero molecular diagnostic system revenues the year before.

For the 12-month period ended Dec. 31, 2016, Curetis' revenues fell to €1.3 million ($1.4 million) from €2.1 million in 2015. The company noted that its 2015 revenues included €900,000 in nonrecurring Unyvero sales to Asian partners for clinical trials and regulatory clearances, as well as €300,000 in pharma revenues.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.